The global gene editing market is expected to grow at a substantial CAGR during the forecast period of 2021-2028. Current developments in gene editing processes have helped the market to reach new heights in the gene editing abilities due to wide advancement in technology for the modification of gene sequences and arrangements of model organisms and cell types. Gene engineering, widely adopted by several research organizations, are increasingly used by government-based research centres and academia and it has now become a great tool for transformative diagnostic and most importantly for oncology studies. The wide application of the process among academics to clinical and diagnostic laboratories is basically influenced by swift changes in gene editing technology. The COVID-19 pandemic has caused problems for many biotechnological and pharmaceutical companies and other players associated with the genomic market as there was radical shift to invest in vaccine research and development of the coronavirus.
Market Trends, Drivers, Restraints, and Opportunities:
- Significant investment in the field of genomics from key players with setting objectives for the development of new technology in gene editing process is expected to boost the market growth during the forecast period.
- Wide involvement of government funding to enable academic and government institutes to carry out in-depth research related to gene editing as well as engineering is a key driver of the market expansion.
- Growth in the personalized medicine market and wide occurrence of gene disorder diseases are expected to offer immense opportunities to players in the gene editing market.
- High cost of gene editing instruments is a major challenge projected to hamper the market growth during the forecast period. The devices equipped with advanced features and high functionalities are normally priced at a range of USD 10-20 million.
Scope of the report:
The report on the global gene editing market includes an assessment of the market, size, share, trends, segments, and regional markets. Overview and dynamics have been included in the report.
Attributes
|
Details
|
Report Title
|
Gene Editing Market – Global Industry Analysis, Growth, Share, Size, Trends, and Forecast
|
Base Year
|
2020
|
Historic Data
|
2018 & 2019
|
Forecast Period
|
2021–2028
|
Segmentation
|
Technology (CRISPR, TALEN, and ZFN), End-users (Pharmaceutical, Biotechnology, and Academia), Applications (Cell Line Engineering, Genetic Engineering, and Diagnostics)
|
Regional Scope
|
Asia Pacific, North America, Europe, Latin America, and Middle East & Africa
|
Report Coverage
|
Market scope, analysis, share, competitive analysis, growth facts, restraints, opportunities, and revenue forecast
|
Key Players Covered
|
Thermo Fisher Scientific Inc.; Merck KGaA; and GenScript
|
Gene Editing Market Segment Insights:
CRISPR segment is projected to account for a significant market share
In terms of the technology, the market is divided into CRISPR, TALEN, and ZFN. The CRISPR segment dominated the market in 2020 and is projected to account for a significant market share during the projected period. The growth of the segment is attributed to wide adoption of the technique as it offers certain practical benefits the genome modification and sequencing. Moreover, wide advantage in illness recovery due to high adoption of a guide RNA-specific, effective gene transformation, and favourable regulation are key aspects, which help to rise in the acceptance of CRISPR technology across hospitals and clinics. Moreover, the clinical uses of CRISPR are widely accepted worldwide due to growing number of gene-editing trails and rapid development of treatment techniques for various diseases such as AIDS, cancer, and genetic diseases. Moreover, this technology is further applied in various animal breeding and agriculture applications.
Pharmaceutical and biotechnological segments are likely to dominate the market
On the basis of end-users, the global gene editing market is segmented into pharmaceutical, biotechnology, and academia. The biotechnology and pharmaceutical segments are likely to dominate the market during the projected period owing to the growing number of research activities for novel therapeutic development for various applications. Moreover, global pharmaceutical companies are collaborating with newly emerging companies to develop novel technologies. However, the academia segment is projected to constitute a key market share in the coming years owing to wide government funding on research collaborated with academic institutes to expedite new genome study and experiments. The segment growth is further attributed to the increasing the number of gene-editing technologies in University-level projects along with active engagement of research institutes.
Cell line engineering segment is anticipated to expand at a robust growth rate
Based on applications, the market is segmented into cell line engineering, genetic engineering, and diagnostics. The cell line engineering segment is anticipated to expand at a robust growth rate in the coming years as the developments in gene editing systems have revolutionized the genetic engineering space, with cell line engineering at the forefront. The usage of CRISPR gene editing in human-induced pluripotent stem cells (hiPSCs) related programs has important effects in stem cell research for the treatment of various diseases. The CRISPR technology is widely being applied to enhance the productivity of CHO cell lines, which are prominently used in the production of large molecule therapeutics.
North America is projected to represent a high market share
In terms of regions, the global gene editing market is categorized as Asia Pacific, North America, Europe, Latin America, and Middle East & Africa. North America accounted for a dominant share of the market, followed by Europe in 2020. The market of North America is projected to represent a high market share during the forecast period owing to the rapid development of gene therapy, increased use of GM crops, and rise in the availability of research grants and funding especially in the US. The market in Canada is expected to register substantial growth in the coming years owing to various government initiatives and the intensification of genomics R&D (through GAPP) in the country.
Segments
Segments covered in the report:
By Technology
By End-users
- Pharmaceutical
- Biotechnology
- Academia
By Applications
- Cell Line Engineering
- Genetic Engineering
- Diagnostics
By Regions
- North America
- Europe
- Latin America
- Asia Pacific
By Key Players
- Thermo Fisher Scientific Inc.
- Merck KGaA
- GenScript
Competitive Landscape
Some of the key players in the market are Thermo Fisher Scientific Inc.; Merck KGaA; and GenScript. These players are actively engaged in various business development strategies including mergers & acquisitions, collaborations, agreements, and partnerships to strengthen their geographical presence.